ABCD nationv	vide cana	a <mark>gliflozin</mark> au	idit – Visit	t <mark>1 d</mark> ata	collectio	on form					
Date	/ /	(	dd/mm/yyyy)	Hospita	l Name			Association of British Clinical Diabetologists			
Name of Clinician				Hospita	l Postcode						
Email				Centre I	.D.						
NHS Number				White	British		Black or Black British	Caribbean			
Forename					Irish	ther White Backgro		└── African └── Any other			
Surname		(	dd/mm/yyyy)	Mixed		and Black Caribbea	n Other Ethnic Groups Ethnic	Chinese			
Date of Birth	/ /				White	Asian ther Mixed Backgro		Any Other Group			
Gender	Male 🗌	Female 🗌		Asian or	Indian						
				Asian British	🗌 Bangla	adeshi					
AFFIX F	PATIENT L	ABEL HERE			1 5	ther Asian Backgrou					
				Height	(metres)						
Baseline medical his	- -			Data of	initiation	of concelliflorin					
Duration of diabetes in years   Date of initiation of canagliflozin   /   /   (dd/mm/yyyy)     Does the patient have a job that would be (or has been) affected by going on insulin (e.g professional driver)?											
Including type of licence if a								C1/C1E (lorries))			
🗌 Not as far as I'm	aware	Yes	_								
If yes please give details including type of licence if appropriate											
Has the patient had			-					_			
Not as far as I am aware Possibly Uncertain Yes How many in total? How many required treatment?											
How many required hospital admission?											
Has the patient had a genital infection (thrush) in the last year? Not as far as I am aware Possibly Uncertain Yes How many in total? How many required treatment?											
Does the patient have urinary incontinence?											
Not as far as I am aware 🗌 Uncertain 🗌 Yes 🗌											
Does the patient have nocturia? Not as far as I am aware Uncertain Yes How many times?											
Has this patient had bariatric surgery?											
□ No □ Yes	Year of surg	ery									
Current antidiabeti			n of Canaglifl	ozin (Invol	kana®)						
Please circle the drugs	that the pation										
Metformin		Metformin		-	-	oined preparations	Total Dose	mg/Day			
Sulphonylurea				nlorpropamide Gliclazide R Tolbutamide Glibenclamide			Total Dose	mg/Day			
Pioglitazone		Pioglitazone     Total dose including any in combined preparati					Total Dose	mg/Day			
Meglitinides	Nateglinide Repaglinide						Total Dose	mg/Day			
Alpha-glucosidase in	nhibitors	ibitors Acarbose					Total Dose	mg/Day			
GLP-1 receptor agon	ists	Exenatide (Micrograms/day)   Liraglutide (Milligrams/day)     Lixisenatide( Micrograms/day)   Exenatide QW (Milligrams/week)					Total Dose	mcg/mg/Day/ Week			
DPP4 inhibitors		Sitagliptin Vildagliptin Saxagliptin Linagliptin Aloglipti					Total Dose	mg/Day			
SGLT2 inhibitors		Dapagliflozin Empagliflozin					Total Dose	mg/Day			
If switching to canagliflozin from another SGLT2 inhibitor please give reason.											
Insulin - Rapid / Sho	rt Acting	Insulin Lispro   Insulin Aspart   Insulin Glulisine     Highly purified Animal   Insulin Human Sequence   Other/Unsure   Plate					Total Dose Please Specify	IU/Day			
Insulin - Long / Inter Acting	mediate	Insulin Detemir   Insulin Glargine   Insulin zinc Suspension   Total Dose     Protamine zinc insulin   Isophane - Highly purified Animal   Please Specify     Isophane - Insulin Human Sequence   Insulin Degludec   Other/Unsure						IU/Day			
Insulin - Biphasic		Biphasic Insulin Bishasic Isopha Bishasic Isopha	ne Insulin – F	luman		2	Total Dose Please Specify	IU/Day			
Other antidiabetic m	nedications	Or medications	which could	affect glyca	aemic cont	rol					
Anit-obesity medica	tion	Orlistat (Xenica	al)			·	Total Dose	mg/Day			

The ABCD nationwide canagliflozin audit is an independent audit supported by an unrestricted grant from Janssen

Test Results						
Blood Pressure SBP DBP	mmHg Date of test mmHg	/ / Current	Weight	kg Date of test	t / / (dd/mm/yyyy)	
HbA1c Percentage		riglyceride Value	mmol/L	Date of test	. / /	
or mmol/mol Date of test /	mmol/mol	HDL Value Total Cholesterol	mmol/L		(dd/mm/yyyy)	
Alanine Aminotransferase - ALT	IU/L Date of measure	/ / Serum Cr	eatinine mr	mol/L Date of measur	, ,	
Medication changes at Canaglif	lozin start	(dd/mm/yyyy)			(dd/mm/yyyy)	
Starting dose of canagliflozin: Diabetes medication not cha Record medication as it will be a	nged at canagliflozin start 🗌			flozin start		
Metformin		cluding any in combined	_	Total Dose	mg/Day	
Sulphonylurea	Glimepiride Glipizide Chlo Gliclazide MR Gliclazide SR	rpropamide Gliclazide Tolbutamide Glibencla	amide	Total Dose	mg/Day	
Pioglitazone	Pioglitazone Total dose in	cluding any in combined	preparations	Total Dose	mg/Day	
Meglitinides	Nateglinide Repaglinide			Total Dose	mg/Day	
Alpha-glucosidase inhibitors	Acarbose			Total Dose	mg/Day	
GLP-1 receptor agonists	Exenatide (Micrograms/day) Lixisenatide (Micrograms/day)	Liraglutide (Milligrams/ Exenatide QW (Microc		Total Dose	mcg/mg/Day/ Week	
DPP4 inhibitors	Sitagliptin Vildagliptin Sax	agliptin Linagliptin A	logliptin	Total Dose	mg/Day	
SGLT2 inhibitors	Dapagliflozin Empagliflozin	]		Total Dose	mg/Day	
Insulin - Rapid / Short Acting	Insulin Lispro Insulin Aspart Highly purified Animal Insul		her/Unsure P	Total Dose	IU/Day	
Insulin - Long / Intermediate Acting	Insulin Detemir Insulin Glarg Protamine zinc insulin Isopha Isophane - Insulin Human Seq	ane - Highly purified Ani	mal	Total Dose	IU/Day	
Insulin - Biphasic	Biphasic Insulin Lispro Bipha Bishasic Isophane Insulin – Hu Bishasic Isophane Insulin – An	man	Ρ	Total Dose	IU/Day	
Other antidiabetic medications						
Anit-obesity medication	Orlistat (Xenical)			Total Dose mg/Day		
Patient opinion of antidiabetic t		1.5 2 2.5 3	3.5 4 4.5	5 5.5 6	mg/Day	
Any other patient comments?			tor/nurse commer			